• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过免疫荧光显微镜技术对来自乳腺癌间充质干细胞异质性群体的人乳腺癌起始细胞进行定位和分子特征分析。

Localization and Molecular Characterization of human Breast Cancer Initiating Cells from heterogeneous population of Breast Cancer Mesenchymal Stem cells by Immunofluorescence Microscopy.

作者信息

Potdar P, Monteiro F

机构信息

Department of Molecular Medicine and Biology, Jaslok Hospital and Research Centre , 15, Dr. G. Deshmukh Road, Mumbai- 400026, Maharashtra, India.

出版信息

J Stem Cells Regen Med. 2012 Nov 26;8(3):190-7. doi: 10.46582/jsrm.0803012. eCollection 2012.

DOI:10.46582/jsrm.0803012
PMID:24693197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3908297/
Abstract

Breast Cancer (BC) is a heterogeneous disease and arises from breast cancer initiating stem cell population in the tumor and these cells are resistant to cancer therapies. Thus identifying this cell type within the tumor clone is an important area of research to understand the mechanism of breast cancer development. Recently, our laboratory has isolated and characterized Human breast cancer mesenchymal stem cells (hBCMSCs) from human breast cancer and showed the heterogeneity of these cells existing in the tumor. Therefore, our present objective is to use this model system to identify, localize and define specific breast cancer initiating cells (BCICs) from the heterogeneous population of hBCMSCs cell line developed in our laboratory. Localization of specific cell types can be done by using specific cancer marker antibodies using Immunofluorescence microscopy. In this study we have used FITC labeled specific cancer antibodies i.e. p53, Rb1, Hras, Ki67, EGFR, GST, ETS1 and ATF2 to localize BCICs in this population of cells. Our results have demonstrated that few cells among many of the BC cells gave fluorescence with specific cancer antibody indicating that these cell types are BCICs that may be responsible for supporting the growth of other cell type to form tumors. The Phase Contrast Microscopy clearly showed giant cells with enlarged nucleus and scanty cytoplasm associated with many cytoplasmic granules. It also indicates that these cells are mainly responsible for supporting proliferation of surrounding cells that form a part of the BC tumor. We have further hypothesized that molecular profiling of these tumor cells will open a new avenue of molecular targeted therapies for Breast Cancer patients even at an advanced stage of disease.

摘要

乳腺癌(BC)是一种异质性疾病,起源于肿瘤中的乳腺癌起始干细胞群体,这些细胞对癌症治疗具有抗性。因此,在肿瘤克隆中识别这种细胞类型是理解乳腺癌发展机制的一个重要研究领域。最近,我们实验室从人类乳腺癌中分离并鉴定了人类乳腺癌间充质干细胞(hBCMSCs),并显示了这些细胞在肿瘤中存在的异质性。因此,我们目前的目标是利用这个模型系统,从我们实验室建立的hBCMSCs细胞系的异质群体中识别、定位和定义特定的乳腺癌起始细胞(BCICs)。特定细胞类型的定位可以通过使用免疫荧光显微镜的特异性癌症标志物抗体来完成。在这项研究中,我们使用了异硫氰酸荧光素(FITC)标记的特异性癌症抗体,即p53、Rb1、Hras、Ki67、表皮生长因子受体(EGFR)、谷胱甘肽S转移酶(GST)、ETS1和活化转录因子2(ATF2),来定位这群细胞中的BCICs。我们的结果表明,许多BC细胞中的少数细胞与特异性癌症抗体产生荧光,表明这些细胞类型是BCICs,可能负责支持其他细胞类型的生长以形成肿瘤。相差显微镜清楚地显示了细胞核增大、细胞质稀少并伴有许多细胞质颗粒的巨大细胞。这也表明这些细胞主要负责支持形成BC肿瘤一部分的周围细胞的增殖。我们进一步推测,这些肿瘤细胞的分子谱分析将为乳腺癌患者开辟一条新的分子靶向治疗途径,即使在疾病的晚期也是如此。

相似文献

1
Localization and Molecular Characterization of human Breast Cancer Initiating Cells from heterogeneous population of Breast Cancer Mesenchymal Stem cells by Immunofluorescence Microscopy.通过免疫荧光显微镜技术对来自乳腺癌间充质干细胞异质性群体的人乳腺癌起始细胞进行定位和分子特征分析。
J Stem Cells Regen Med. 2012 Nov 26;8(3):190-7. doi: 10.46582/jsrm.0803012. eCollection 2012.
2
Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.原发性浸润性乳腺癌治疗前核心活检中的Ki67和淋巴细胞:治疗反应预测的阳性标志物及更好的生存率
Horm Mol Biol Clin Investig. 2017 Sep 22;32(2):/j/hmbci.2017.32.issue-2/hmbci-2017-0022/hmbci-2017-0022.xml. doi: 10.1515/hmbci-2017-0022.
3
Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines.双受体靶向(DRT)放射性纳米药物与 Lu 标记后,对于杀伤同时表达 HER2 和 EGFR 的人乳腺癌细胞,比单受体靶向(SRT)放射性纳米药物更有效。
Mol Pharm. 2020 Apr 6;17(4):1226-1236. doi: 10.1021/acs.molpharmaceut.9b01259. Epub 2020 Mar 3.
4
Use of multiple biomarkers for the localization and characterization of colon cancer stem cells by indirect immunocytochemistry.间接免疫细胞化学法使用多种生物标志物定位和鉴定结肠癌干细胞。
Int J Oncol. 2012 Jul;41(1):285-91. doi: 10.3892/ijo.2012.1430. Epub 2012 Apr 10.
5
Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.靶向成像和抑制三阴性乳腺癌转移的 PDGFRβ 适体。
Theranostics. 2018 Oct 6;8(18):5178-5199. doi: 10.7150/thno.27798. eCollection 2018.
6
Significance of heterogeneous Twist2 expression in human breast cancers.人乳腺癌中 Twist2 表达异质性的意义。
PLoS One. 2012;7(10):e48178. doi: 10.1371/journal.pone.0048178. Epub 2012 Oct 25.
7
A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.非生物活性截短型表皮生长因子(EGFt)与全长人表皮生长因子(hEGF)在将发射俄歇电子的铟-111递送至无胸腺小鼠的表皮生长因子受体(EGFR)阳性乳腺癌细胞及肿瘤异种移植物中的比较。
Nucl Med Biol. 2015 Dec;42(12):931-8. doi: 10.1016/j.nucmedbio.2015.08.003. Epub 2015 Aug 19.
8
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.在乳腺癌中靶向 EGFR 依赖性肿瘤起始程序。
Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
9
RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.RB1 和 p53 在 EMT 和三阴性乳腺癌的交汇点。
Cell Cycle. 2011 May 15;10(10):1563-70. doi: 10.4161/cc.10.10.15703.
10
Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.抑制表皮生长因子受体信号传导可增强乳腺癌干细胞的间充质-上皮转化及其对抗癌药物的反应性。
FEBS J. 2017 Jun;284(12):1830-1854. doi: 10.1111/febs.14084. Epub 2017 May 16.

本文引用的文献

1
Breast cancer-initiating cells: insights into novel treatment strategies.乳腺癌起始细胞:新型治疗策略的新视角。
Cancers (Basel). 2011 Mar 16;3(1):1405-25. doi: 10.3390/cancers3011405.
2
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
3
Drug resistant breast cancer cells overexpress ETS1 gene.耐药性乳腺癌细胞过度表达 ETS1 基因。
Biomed Pharmacother. 2010 Sep;64(7):458-62. doi: 10.1016/j.biopha.2010.01.008. Epub 2010 Feb 25.
4
Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.活化转录因子2(ATF2)及其磷酸化形式在乳腺癌中的表达及预后价值
Anticancer Res. 2009 Jan;29(1):183-9.
5
Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells.Ets-1上调乳腺癌细胞中HER2诱导的MMP-1表达。
Biochem Biophys Res Commun. 2008 Dec 12;377(2):389-394. doi: 10.1016/j.bbrc.2008.09.135. Epub 2008 Oct 11.
6
The biology of cancer stem cells.癌症干细胞的生物学
Annu Rev Cell Dev Biol. 2007;23:675-99. doi: 10.1146/annurev.cellbio.22.010305.104154.
7
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.I型胰岛素样生长因子受体的下调增加了乳腺癌细胞对胰岛素的敏感性。
Cancer Res. 2007 Jan 1;67(1):391-7. doi: 10.1158/0008-5472.CAN-06-1712.
8
Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells.激活转录因子2介导p38在乳腺上皮细胞中诱导的基质金属蛋白酶-2转录激活。
Cancer Res. 2006 Nov 1;66(21):10487-96. doi: 10.1158/0008-5472.CAN-06-1461.
9
Expression of retinoblastoma protein in breast cancer metastases to sentinel nodes: evaluation of its role as a marker for the presence of metastases in non-sentinel axillary nodes, and comparison to p16INK4a.视网膜母细胞瘤蛋白在乳腺癌前哨淋巴结转移中的表达:评估其作为非前哨腋窝淋巴结转移存在标志物的作用,并与p16INK4a进行比较。
Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):63-70. doi: 10.1097/01.pai.0000161486.72621.4a.
10
Aberrant activation of notch signaling in human breast cancer.人类乳腺癌中Notch信号通路的异常激活。
Cancer Res. 2006 Feb 1;66(3):1517-25. doi: 10.1158/0008-5472.CAN-05-3054.